DrugPatentWatch serves leading companies ranging from biopharmaceutical R&D to healthcare delivery, and has been cited by CNN, NEJM, Nature Journals, and many other leading publications. Use cases for the DrugPatentWatch platform include: - Branded pharmaceutical global business intelligence and forecasting - Generic drug and API manufacturer portfolio management - Wholesalers preventing overstock of off-patent drugs - Healthcare payer formulary management and budget management
…
continue reading
Chiral switching, the practice of developing a single enantiomer from a previously approved racemic drug, has been a significant strategy […]SourceDrugPatentWatch
…
continue reading
Developing a competitive edge in generic drug development is crucial for companies to gain a significant market share and dominate […]SourceDrugPatentWatch
…
continue reading
To identify Key Starting Materials (KSMs) for Active Pharmaceutical Ingredients (APIs), pharmaceutical companies and regulatory bodies follow a systematic approach […]SourceDrugPatentWatch
…
continue reading
The generic drug market has been significantly impacted by the COVID-19 pandemic, with both challenges and opportunities arising from the […]SourceDrugPatentWatch
…
continue reading
In the high-stakes world of pharmaceuticals, generic drugs have become the unsung heroes of healthcare accessibility. These cost-effective alternatives to […]SourceDrugPatentWatch
…
continue reading
In the high-stakes world of pharmaceutical innovation, drafting detailed drug patent claims is a critical process that can make or […]SourceDrugPatentWatch
…
continue reading
As patents expire on blockbuster biologic drugs, manufacturers are increasingly employing a controversial tactic known as “product hopping” to maintain […]SourceDrugPatentWatch
…
continue reading
Enantiomer Switching: A Pharmaceutical Strategy to Extend Drug Patents Enantiomer switching, also known as chiral switching, is a strategy employed […]SourceDrugPatentWatch
…
continue reading
In the rapidly evolving landscape of biosimilars, intellectual property (IP) strategy is paramount. Biosimilar manufacturers face unique challenges, including navigating […]SourceDrugPatentWatch
…
continue reading
Introduction The Patent Trial and Appeal Board (PTAB) is a crucial component of the United States Patent and Trademark Office […]SourceDrugPatentWatch
…
continue reading
Transitioning to a new Contract Development and Manufacturing Organization (CDMO) can be a complex and challenging process. However, by following […]SourceDrugPatentWatch
…
continue reading
The High Stakes of Pharmaceutical Patent Litigation In the fiercely competitive pharmaceutical industry, patent disputes can make or break a […]SourceDrugPatentWatch
…
continue reading
Introduction Patent oppositions are a crucial tool in the pharmaceutical industry, allowing civil society to challenge the validity of patents […]SourceDrugPatentWatch
…
continue reading
The Strategic Advantage of Complex Drug Delivery Systems In the highly competitive pharmaceutical landscape, adopting complex drug delivery systems can […]SourceDrugPatentWatch
…
continue reading
An HHS report titled “The Potential Role of The Nonprofit Pharmaceutical Industry in Addressing Shortages and Increasing Access to Essential […]SourceDrugPatentWatch
…
continue reading
The value proposition of Contract Development and Manufacturing Organizations (CDMOs) has become increasingly crucial in the pharmaceutical industry. As the […]SourceDrugPatentWatch
…
continue reading
In the high-stakes world of biosimilar development, manufacturers are increasingly turning to an unexpected partner: the Patent Trial and Appeal […]SourceDrugPatentWatch
…
continue reading
This is an example from the DrugPatentWatch AI Research Assistant, which is available with DrugPatentWatch subscriptions. The DrugPatentWatch AI Research […]SourceDrugPatentWatch
…
continue reading
The introduction of biosimilars has significantly altered the landscape of biologic drug distribution models. Biosimilars, which are highly similar to […]SourceDrugPatentWatch
…
continue reading
In a seismic shift for European intellectual property, the Unified Patent Court (UPC) is rapidly transforming how businesses approach patent […]SourceDrugPatentWatch
…
continue reading
To find low-competition generic drug opportunities, focus on drugs with limited competition due to small patient populations, complex formulations, or […]SourceDrugPatentWatch
…
continue reading
The integration of artificial intelligence (AI) into drug discovery and development is revolutionizing the pharmaceutical industry. AI’s ability to analyze […]SourceDrugPatentWatch
…
continue reading
China is emerging as a global frontrunner in patenting artificial intelligence (AI) technologies for drug discovery, particularly in the field […]SourceDrugPatentWatch
…
continue reading
The pharmaceutical industry is a high-stakes arena where innovation, investment, and intellectual property (IP) protection intersect. One of the most […]SourceDrugPatentWatch
…
continue reading
Lipitor’s marketing strategy underwent a significant evolution as generic competition emerged, employing aggressive tactics to retain market share and brand […]SourceDrugPatentWatch
…
continue reading
Patent Expirations and Generic Competition This week saw several major blockbuster drugs facing patent expirations, potentially opening the market for […]SourceDrugPatentWatch
…
continue reading
Introduction Patent portfolios are critical assets for pharmaceutical companies, providing market exclusivity and protecting revenue streams for drug products. Effective […]SourceDrugPatentWatch
…
continue reading
This is an example from the DrugPatentWatch AI Research Assistant, which is available with DrugPatentWatch subscriptions. The DrugPatentWatch AI Research […]SourceDrugPatentWatch
…
continue reading
Introduction In the rapidly evolving landscape of pharmaceutical patent disputes in China, injunctive relief has emerged as a critical tool […]SourceDrugPatentWatch
…
continue reading
DrugChatter is an innovative AI-powered search and answer engine designed to revolutionize how we access and comprehend information. Harnessing the […]SourceDrugPatentWatch
…
continue reading
![Artwork](/static/images/128pixel.png)
1
USPTO Study Reveals Trends and Insights into Drug Patent and Exclusivity Trends in the Pharmaceutical Industry
Introduction: The United States Patent and Trademark Office (USPTO) has recently released a comprehensive study on drug patents and exclusivity […]SourceDrugPatentWatch
…
continue reading
The 505(b)(2) regulatory pathway provides an attractive avenue for drug developers to bring new products to market by leveraging existing […]SourceDrugPatentWatch
…
continue reading
In the high-stakes world of pharmaceuticals, patents play a pivotal role in safeguarding intellectual property and ensuring a return on […]SourceDrugPatentWatch
…
continue reading
In the ever-evolving pharmaceutical landscape, savvy businesses are constantly on the lookout for untapped markets and lucrative opportunities. One area […]SourceDrugPatentWatch
…
continue reading
Branded generics are generic drugs that are marketed under a brand name by the manufacturer. These products contain the same […]SourceDrugPatentWatch
…
continue reading
A recent whitepaper by Hermann Mucke summarizes the steps to performing an FTO for drug repurposing: Overview An FtO analysis […]SourceDrugPatentWatch
…
continue reading
The article “The devil is in the divisional: an analysis of divisional patents, deadlines, declarations and suggestions for future practice” […]SourceDrugPatentWatch
…
continue reading
Pharmaceutical companies employ various strategies to extend the commercial life and patent protection of successful drugs. Here are some key […]SourceDrugPatentWatch
…
continue reading
Sure, here’s a more detailed explanation with examples: Drug Patent Duration Drug patents are granted by the United States Patent […]SourceDrugPatentWatch
…
continue reading
In the “Patent Effect” podcast, Mustafa introduces his guest, Hakan Yum, the IP Director of Exrain Pharma, based in Sweden. […]SourceDrugPatentWatch
…
continue reading
In a recent study published in the Expert Review of Medical Devices, researchers investigated the utilization of patent term extensions […]SourceDrugPatentWatch
…
continue reading
Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate […]SourceDrugPatentWatch
…
continue reading
The pharmaceutical industry in China is undergoing a significant transformation with the adoption of artificial intelligence (AI) technology. A recent […]SourceDrugPatentWatch
…
continue reading
A paper presented at the 2nd International Conference on Systems Medicine, AI, and Drug Repurposing proposes a novel approach to […]SourceDrugPatentWatch
…
continue reading
A recent study published in JAMA Health Forum sheds light on the impact of biosimilar competition on patient out-of-pocket (OOP) […]SourceDrugPatentWatch
…
continue reading
A recent article in Communications of the ACM explores opportunities for “Permissionless innovation” in pharmaceuticals. “Permissionless innovation” refers to the […]SourceDrugPatentWatch
…
continue reading
LACTOSE-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Lactose-Free Medicines from Amazon This […]SourceDrugPatentWatch
…
continue reading
GELATIN-Free Medicines, 2024 is part of DrugPatentWatch’s deep library of business intelligence on biopharmaceutical drugs. Buy Gelatin-Free Medicines on Amazon This […]SourceDrugPatentWatch
…
continue reading
Switching pharmaceutical excipients, the inactive components used in drug formulations, can have significant implications for both production costs and market […]SourceDrugPatentWatch
…
continue reading
Elevate your excipient business strategies with the comprehensive Drug Excipient Business Development Reports from DrugPatentWatch. Designed for excipient manufacturers seeking […]SourceDrugPatentWatch
…
continue reading